Research Platform Degenerative Diseases, German Primate Center-Leibniz Institute for Primate Research, Kellnerweg 4, 37077 Göttingen, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, 37075 Göttingen, Germany.
Cells. 2024 Mar 21;13(6):558. doi: 10.3390/cells13060558.
Non-human primates (NHPs) are pivotal animal models for translating novel cell replacement therapies into clinical applications, including validating the safety and efficacy of induced pluripotent stem cell (iPSC)-derived products. Preclinical development and the testing of cell-based therapies ideally comprise xenogeneic (human stem cells into NHPs) and allogenic (NHP stem cells into NHPs) transplantation studies. For the allogeneic approach, it is necessary to generate NHP-iPSCs with generally equivalent quality to the human counterparts that will be used later on in patients. Here, we report the generation and characterization of transgene- and feeder-free cynomolgus monkey () iPSCs (Cyno-iPSCs). These novel cell lines have been generated according to a previously developed protocol for the generation of rhesus macaque, baboon, and human iPSC lines. Beyond their generation, we demonstrate the potential of the novel Cyno-iPSCs to differentiate into two clinically relevant cell types, i.e., cardiomyocytes and neurons. Overall, we provide a resource of novel iPSCs from the most frequently used NHP species in the regulatory testing of biologics and classical pharmaceutics to expand our panel of iPSC lines from NHP species with high relevance in preclinical testing and translational research.
非人类灵长类动物(NHPs)是将新型细胞替代疗法转化为临床应用的关键动物模型,包括验证诱导多能干细胞(iPSC)衍生产品的安全性和有效性。临床前开发和细胞疗法的测试理想情况下包括异种(人干细胞到 NHP)和同种异体(NHP 干细胞到 NHP)移植研究。对于同种异体方法,有必要生成与以后用于患者的人类对应物具有相当质量的 NHP-iPSC。在这里,我们报告了转基因和无饲养层食蟹猴()iPSC(Cyno-iPSC)的生成和表征。这些新的细胞系是根据先前开发的恒河猴、狒狒和人 iPSC 系生成的方案生成的。除了生成之外,我们还证明了新型 Cyno-iPSC 分化为两种临床相关细胞类型的潜力,即心肌细胞和神经元。总的来说,我们提供了一种新型 iPSC 资源,来自于在生物制品和经典药物的监管测试中最常用的 NHP 物种,以扩大我们具有高度临床前测试和转化研究相关性的 NHP 物种 iPSC 系的面板。